About: Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of anti-infective therapy (SITA) and the Italian Society of Pulmonology (SIP)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of anti-infective therapy (SITA) and the Italian Society of Pulmonology (SIP) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of anti-infective therapy (SITA) and the Italian Society of Pulmonology (SIP)
Creator	Blasi, Francesco Bassetti, Matteo Aliberti, Stefano Santus, Pierachille Gori, Andrea Petrosillo, Nicola Granata, Guido Mikulska, Malgorzata De Rosa, Francesco Marco, Fabiano Richeldi, Luca Barisione, Emanuela Centanni, Stefano Giacobbe, Daniele Paolo, Santi Tascini, Carlo Vena, Antonio Viale, Pierluigi Bassetti, Marco, Di Carlo, Milan Martino -Irccs, San Policlinico, Ospedale
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: SARS-CoV-2 is the causative agent of coronavirus disease 2019 (COVID-19), which has rapidly become epidemic in Italy and other European countries. The disease spectrum ranges from asymptomatic/mildly symptomatic presentations to acute respiratory failure. At the present time the absolute number of severe cases requiring ventilator support is reaching or even surpassing the intensive care unit bed capacity in the most affected regions and countries. OBJECTIVES: To narratively summarize the available literature on the management of COVID-19, in the attempt to combine current evidence and frontline opinions and provide balanced answers to pressing clinical questions. SOURCES: Inductive PubMed search for publications relevant to the topic. CONTENT: The available literature and the authors’ frontline-based opinion are summarized in brief narrative answers to selected clinical questions, plus a conclusive statement for each answer. IMPLICATIONS: Many off-label antiviral and anti-inflammatory drugs are currently being administered to patients with COVID-19. Physicians must be aware that, being not supported by high-level evidence, these treatments may often be ethically justifiable only in those worsening patients unlikely to improve only with supportive care, and who cannot be enrolled in randomized clinical trials (RCT). Access to well-designed RCT should be expanded as much as possible, being the most secure way to change for the better our approach to COVID-19 patients.
has issue date	2020-04-29(xsd:dateTime)
bibo:doi	10.1016/j.cmi.2020.04.031
bibo:pmid	32360444
has license	no-cc
sha1sum (hex)	08facf5aadfcaff28707580c3b59dbc3441f3a76
schema:url	https://doi.org/10.1016/j.cmi.2020.04.031
resource representing a document's title	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of anti-infective therapy (SITA) and the Italian Society of Pulmonology (SIP)
has PubMed Central identifier	PMC7195088
has PubMed identifier	32360444
schema:publication	Clin Microbiol Infect
resource representing a document's body	covid:08facf5aadfcaff28707580c3b59dbc3441f3a76#body_text
is schema:about of	named entity 'reaching' named entity 'capacity' named entity 'frontline' named entity 'Balancing' named entity 'phases' named entity 'phases' named entity 'position' named entity 'spectrum' named entity 'regions' named entity 'management' named entity 'authors' named entity 'causative' named entity 'frontline' named entity 'Italian' named entity 'SARS-CoV-2' named entity 'Italy' named entity 'ventilator support' named entity 'Pulmonology' named entity 'Italian Society' named entity 'Pulmonology' named entity 'SITA' named entity 'COVID-19 pandemic' named entity 'Italian Society' named entity 'Italian Society' named entity 'HFNC' named entity 'lung failure' named entity 'Tocilizumab' named entity 'follow-up' named entity 'systemic inflammation' named entity 'infection' named entity 'lung' named entity 'steroid' named entity 'treatment of patients' named entity 'SARS-CoV-2' named entity 'viral pneumonia' named entity 'oxygen' named entity 'oxygen' named entity 'SITA' named entity 'HFNC' named entity 'clinical findings' named entity 'COVID' named entity 'toxicity' named entity 'HFNC' named entity 'favipiravir' named entity 'Oseltamivir' named entity 'RCT' named entity 'observational study' named entity 'hydroxychloroquine' named entity 'China' named entity 'China' named entity 'RCT' named entity 'coronaviruses' named entity 'respiratory failure' named entity 'SARS-CoV-1' named entity 'QT prolongation' named entity 'RCT' named entity 'COVID-19' named entity 'COVID' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software